The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.
Nishith K. Singh
No relevant relationships to disclose
Marijo Bilusic
No relevant relationships to disclose
Joseph W. Kim
No relevant relationships to disclose
Christopher Ryan Heery
No relevant relationships to disclose
Martin H. Falk
Employment or Leadership Position - Merck KGaA
Consultant or Advisory Role - Merck KGaA
Bradford J Wood
No relevant relationships to disclose
Peter A. Pinto
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose
Aradhana Kaushal
No relevant relationships to disclose
Anna Couvillon
No relevant relationships to disclose
Myrna Rauckhorst
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Ismail B. Turkbey
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Kwong Yok Tsang
No relevant relationships to disclose
Jeffrey Schlom
No relevant relationships to disclose
James L. Gulley
Research Funding - Merck KGaA
Ravi A. Madan
No relevant relationships to disclose